Inoviq Ltd (AU:IIQ) has released an update.
INOVIQ Ltd has announced a strategic global partnership with Promega Corporation, signaling a significant leap in distributing its EXO-NET technology to researchers worldwide, aiming to discover new diagnostic and therapeutic uses for exosomes. The company has begun earning revenue from this collaboration and is also advancing its own cancer tests, with recent studies showing its neuCA15-3 test outperforming existing breast cancer tests. With a healthy cash balance and ongoing research in various medical applications, including promising studies in Alzheimer’s and Parkinson’s diseases, INOVIQ is poised for transformative impacts in medical research and patient care.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.
